AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies
The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.
You may also be interested in...
Deal Snapshot: Set to begin a Phase II study that Alpine will complete, ALPN-101 is a dual inhibitor of CD28 and ICOS that may offer a new treatment option in SLE.
AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.